FDA gives 510(k) approval to Gmate SMART Blood Glucose Monitoring System for diabetes- Philosys
The FDA has given 510(k) approval for the Gmate SMART Blood Glucose Monitoring System and App for Android, from Philosys, for people with diabetes. The device is a small, portable blood glucose meter that plugs into the headphone jack of a smartphone and provides fast and accurate blood glucose test results.
Together, the Gmate SMART Meter and App turn a smartphone into a mobile blood glucose monitoring system. The Gmate SMART Meter is the size of a coin and connects to the headphone jack of the smartphone. The Gmate SMART App integrates diabetes management directly to the iOS or Android device, providing diabetes management including goal setting, graphing and the ability to email or text blood glucose test results directly to a family member or healthcare provider.
Comment: According to Center for Technology Innovation at Brookings, the use of mobile technologies that monitor patient symptoms and provide real-time treatment options have the potential to control costs, reduce errors, and improve the overall patient experience in chronic conditions such as diabetes.
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)